Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
作者： Jaime E Ordóñez , John J Orozco
关键词:
摘要: Background: Nowadays, there are two vaccination strategies in Colombia to prevent pneumococcal diseases people over 50 years. Our aim is estimate cost-effectiveness of conjugate vaccine 13-valent (PCV13) versus polysaccharide 23-valent (PPSV23) and their related mortality years old Colombia. Methods: A Markov model was developed with national data, including serotypes distribution between 2005 2010. Vaccination a cohort simulated five year time horizon assumed. Analysis done from perspective third party payer. Direct costs were provided by insurance company; sensitive univariate probabilistic analysis for epidemiological clinical effectiveness parameters costs.
biomedcentral.com
springer.com
sci-hub.se 参考文章(51)
John D. Grabenstein, Megan A. O’Brien, Jieling Chen, Cost-effectiveness of adult pneumococcal vaccination: responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012;30(August (36)):5437-44. Vaccine. ,vol. 31, pp. 1549- ,(2013) , 10.1016/J.VACCINE.2012.10.110
I.D. Riley, M. Andrews, R. Howard, P.I. Tarr, M. Pfeiffer, P. Challands, G. Jennison, R.M. Douglas, IMMUNISATION WITH A POLYVALENT PNEUMOCOCCAL VACCINE: Reduction of Adult Respiratory Mortality in a New Guinea Highlands Community The Lancet. ,vol. 309, pp. 1338- 1341 ,(1977) , 10.1016/S0140-6736(77)92552-1
World Health Organization, None, Making Choices in Health: WHO Guide to Cost Effectiveness Analysis ,(2003)
A Gervais, J A Leech, F L Ruben, Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease Canadian Medical Association Journal. ,vol. 136, pp. 361- 365 ,(1987)
Carlos Castañeda-Orjuela, Nelson Alvis-Guzmán, Fernando De la Hoz-Restrepo, None, Impacto de la enfermedad por Streptococcus pneumoniae en población adulta mayor en Bogotá, Colombia, 2008 Revista de salud publica (Bogota, Colombia). ,vol. 12, pp. 38- 50 ,(2010) , 10.1590/S0124-00642010000100004
Alicia M Fry, Elizabeth R Zell, Anne Schuchat, Jay C Butler, Cynthia G Whitney, Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. ,vol. 21, pp. 303- 311 ,(2002) , 10.1016/S0264-410X(02)00451-6
Carlos Castañeda-Orjuela, Nelson Alvis-Guzmán, Ángel José Paternina, Fernando De la Hoz-Restrepo, Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. Vaccine. ,vol. 29, pp. 7644- 7650 ,(2011) , 10.1016/J.VACCINE.2011.08.006
John Hansen, Steven Black, Henry Shinefield, Thomas Cherian, Jane Benson, Bruce Fireman, Edwin Lewis, Paula Ray, Janelle Lee, Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatric Infectious Disease Journal. ,vol. 25, pp. 779- 781 ,(2006) , 10.1097/01.INF.0000232706.35674.2F
Colin M. MacLeod, Richard G. Hodges, Michael Heidelberger, William G. Bernhard, PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES Journal of Experimental Medicine. ,vol. 82, pp. 445- 465 ,(1945) , 10.1084/JEM.82.6.445
Anne L. Davis, Conrado P. Aranda, Gerald Schiffman, Lynn C. Christianson, Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease: a pilot study Chest. ,vol. 92, pp. 204- 212 ,(1987) , 10.1378/CHEST.92.2.204